{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T08:38:32Z","timestamp":1792485512328,"version":"4.5.0"},"reference-count":49,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100020098","name":"Innovative Health Initiative","doi-asserted-by":"publisher","award":["101112145"],"award-info":[{"award-number":["101112145"]}],"id":[{"id":"10.13039\/100020098","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020098","name":"Innovative Health Initiative","doi-asserted-by":"publisher","award":["101132933"],"award-info":[{"award-number":["101132933"]}],"id":[{"id":"10.13039\/100020098","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018713","name":"Center for Innovative Medicine","doi-asserted-by":"publisher","award":["FoUI\u2010104172"],"award-info":[{"award-number":["FoUI\u2010104172"]}],"id":[{"id":"10.13039\/501100018713","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013278","name":"EU Joint Programme \u2013 Neurodegenerative Disease Research","doi-asserted-by":"publisher","award":["357810"],"award-info":[{"award-number":["357810"]}],"id":[{"id":"10.13039\/100013278","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008599","name":"Alzheimerfonden","doi-asserted-by":"publisher","award":["AF\u20101031812"],"award-info":[{"award-number":["AF\u20101031812"]}],"id":[{"id":"10.13039\/501100008599","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2025\u201002405"],"award-info":[{"award-number":["2025\u201002405"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006129","name":"Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003792","name":"Hj\u00e4rnfonden","doi-asserted-by":"publisher","award":["FO2026\u20100228"],"award-info":[{"award-number":["FO2026\u20100228"]}],"id":[{"id":"10.13039\/501100003792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006636","name":"Forskningsr\u00e5det f\u00f6r h\u00e4lsa, arbetsliv och v\u00e4lf\u00e4rd","doi-asserted-by":"publisher","award":["2025\u201002071"],"award-info":[{"award-number":["2025\u201002071"]}],"id":[{"id":"10.13039\/501100006636","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001858","name":"VINNOVA","doi-asserted-by":"publisher","award":["2025\u201003749"],"award-info":[{"award-number":["2025\u201003749"]}],"id":[{"id":"10.13039\/501100001858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Euro J of Neurology"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Anti\u2010amyloid therapies lecanemab and donanemab are the first potentially disease\u2010modifying treatments for Alzheimer's disease (AD) approved in Europe. We estimated real\u2010world eligibility for these treatments in a large multicenter memory clinic patient cohort in Sweden (MemClin).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>MemClin included patients with a first diagnostic visit between 2016 and 2022 at seven specialist memory clinics in Stockholm, Sweden. To estimate eligibility for anti\u2010amyloid therapy, we applied key inclusion\/exclusion criteria from the lecanemab and donanemab appropriate use recommendations. Eligible patients were required to have (1) a clinical diagnosis of AD\u2010type dementia or mild cognitive impairment (MCI), (2) confirmed A\u03b2 pathology (abnormal CSF A\u03b242) and (3) no apparent medical exclusion criteria. Eligibility was calculated for different scenarios to provide both upper\u2010bound estimates (main analysis) and more conservative, implementation\u2010ready estimates of near\u2010term treatable patients (sensitivity analysis).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Cohort consisted of 2126 patients (mean age 77.1\u2009\u00b1\u20096.6\u2009years; 61.8% MCI, 24.2% dementia, 13.7% subjective cognitive impairment). In the main analysis, 11.5% of the whole cohort was estimated to be eligible for either treatment (lecanemab 10.6%, donanemab 11.5%). Most eligible patients had early\u2010stage disease (61.9% MCI vs. 38.1% dementia) and an A\u2009+\u2009T\u2013 biomarker profile, that is, normal biomarker of tau (57.9%). Eligibility was markedly lower in sensitivity analyses (e.g., 2.7% when all patients without MRI were assumed ineligible).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Even upper\u2010bound estimates indicate that a minority of real\u2010world memory clinic patients may currently qualify for anti\u2010amyloid therapy. These findings provide timely evidence to inform the ongoing debate on the implementation of anti\u2010amyloid therapy in public healthcare.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ene.70786","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T07:41:13Z","timestamp":1792482073000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real\u2010World Patient Eligibility for Alzheimer's Disease Anti\u2010Amyloid Therapy in Seven Swedish Memory Clinics"],"prefix":"10.1111","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1456-7991","authenticated-orcid":false,"given":"Anna","family":"Rosenberg","sequence":"first","affiliation":[{"name":"Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society Karolinska Institutet  Stockholm Sweden"},{"name":"Institute of Public Health and Clinical Nutrition University of Eastern Finland  Kuopio Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0976-8062","authenticated-orcid":false,"given":"Anna","family":"Rennie","sequence":"additional","affiliation":[{"name":"Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society Karolinska Institutet  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3926-8656","authenticated-orcid":false,"given":"Urban","family":"Ekman","sequence":"additional","affiliation":[{"name":"Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society Karolinska Institutet  Stockholm Sweden"},{"name":"Women's Health and Allied Health Professionals Theme Karolinska University Hospital  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5460-9802","authenticated-orcid":false,"given":"Makrina","family":"Daniilidou","sequence":"additional","affiliation":[{"name":"Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society Karolinska Institutet  Stockholm Sweden"},{"name":"FINGERS Brain Health Institute  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anette","family":"Hall","sequence":"additional","affiliation":[{"name":"Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society Karolinska Institutet  Stockholm Sweden"},{"name":"Department of Neurology, Institute of Clinical Medicine University of Eastern Finland  Kuopio Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7819-0495","authenticated-orcid":false,"given":"Anna","family":"Matton","sequence":"additional","affiliation":[{"name":"Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society Karolinska Institutet  Stockholm Sweden"},{"name":"FINGERS Brain Health Institute  Stockholm Sweden"},{"name":"Ageing Epidemiology (AGE) Research Unit, School of Public Health Imperial College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari","family":"Solomon","sequence":"additional","affiliation":[{"name":"Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society Karolinska Institutet  Stockholm Sweden"},{"name":"Department of Neurology, Institute of Clinical Medicine University of Eastern Finland  Kuopio Finland"},{"name":"Ageing Epidemiology (AGE) Research Unit, School of Public Health Imperial College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars\u2010Olof","family":"Wahlund","sequence":"additional","affiliation":[{"name":"Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society Karolinska Institutet  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miia","family":"Kivipelto","sequence":"additional","affiliation":[{"name":"Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society Karolinska Institutet  Stockholm Sweden"},{"name":"Institute of Public Health and Clinical Nutrition University of Eastern Finland  Kuopio Finland"},{"name":"Ageing Epidemiology (AGE) Research Unit, School of Public Health Imperial College London  London UK"},{"name":"Theme Inflammation and Aging Karolinska University Hospital  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3115-2977","authenticated-orcid":false,"given":"Eric","family":"Westman","sequence":"additional","affiliation":[{"name":"Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society Karolinska Institutet  Stockholm Sweden"},{"name":"Ageing Epidemiology (AGE) Research Unit, School of Public Health Imperial College London  London UK"},{"name":"Theme Inflammation and Aging Karolinska University Hospital  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,20]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.13239"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(25)01329\u20107"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2023.30"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100150"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp\u20102025\u2010336"},{"key":"e_1_2_14_8_1","unstructured":"European Medicines Agency \u201cLeqembi: EPAR\u2014Product Information \u201d(2025) https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/leqembi\u2010epar\u2010product\u2010information_en.pdf."},{"key":"e_1_2_14_9_1","unstructured":"European Commission \u201cKisunla: EPAR\u2014Product Information \u201d(2025) https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/kisunla\u2010epar\u2010product\u2010information_en.pdf."},{"key":"e_1_2_14_10_1","unstructured":"Alzheimer Europe \u201cNICE Publishes Final Guidance Recommending Against Routine NHS Use of Donanemab and Lecanemab \u201d(2025) https:\/\/www.alzheimer\u2010europe.org\/news\/nice\u2010publishes\u2010final\u2010guidance\u2010recommending\u2010against\u2010routine\u2010nhs\u2010use\u2010donanemab\u2010and\u2010lecanemab?language_content_entity=en."},{"key":"e_1_2_14_11_1","unstructured":"Alzheimer Europe \u201cThe Haute Autorit\u00e9 de Sant\u00e9 Issues Decision Refusing to Grant Early Access (Acc\u00e8s Pr\u00e9coce) to Lecanemab in France \u201d(2025) https:\/\/www.alzheimer\u2010europe.org\/news\/haute\u2010autorite\u2010de\u2010sante\u2010issues\u2010decision\u2010refusing\u2010grant\u2010early\u2010access\u2010acces\u2010precoce\u2010lecanemab."},{"key":"e_1_2_14_12_1","unstructured":"NT Council (NT\u2010r\u00e5det) \u201cSwedish NT Council Recommendation for the Use of Leqembi (Lecanemab) in Alzheimer's Disease \u201d(2026) https:\/\/samverkanlakemedel.se\/download\/18.8fcd48619d9a5d8bb1411\/1776414584927\/LeqembividAlzheimerssjukdom2026\u201004\u201017.pdf."},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195\u2010025\u201001766\u2010y"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2026.101609"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2025.02.007"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12694"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000201043"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100476"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12877\u2010020\u20101478\u20103"},{"key":"e_1_2_14_20_1","unstructured":"Swedish National Board for Health and Welfare \u201cNationella Riktlinjer F\u00f6r V\u00e5rd Och Omsorg Vid Demenssjukdom \u201d(2017) https:\/\/www.socialstyrelsen.se\/kunskapsstod\u2010och\u2010regler\/regler\u2010och\u2010riktlinjer\/nationella\u2010riktlinjer\/riktlinjer\u2010och\u2010utvarderingar\/demens\/."},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102796.2004.01380.x"},{"issue":"6","key":"e_1_2_14_22_1","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1161\/01.STR.32.6.1318","article-title":"A New Rating Scale for Age\u2010Related White Matter Changes Applicable to MRI and CT","volume":"32","author":"Wahlund L. O.","year":"2001","journal-title":"Stroke"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.55.10.967"},{"key":"e_1_2_14_24_1","first-page":"95","article-title":"Qualitative Assessment of Cerebral Atrophy on MRI: Inter\u2010and\u2010Intra\u2010Observer Reproducibility in Dementia and Normal Aging","volume":"37","author":"Scheltens P.","year":"1997","journal-title":"European Neurology"},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13244\u2010016\u20100521\u20106"},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.02.018"},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12358"},{"key":"e_1_2_14_28_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2023.44"},{"key":"e_1_2_14_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70375"},{"key":"e_1_2_14_30_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209402"},{"key":"e_1_2_14_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/gps.5789"},{"key":"e_1_2_14_32_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207770"},{"key":"e_1_2_14_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/gps.6157"},{"key":"e_1_2_14_34_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjo.2024.747"},{"key":"e_1_2_14_35_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp\u20102024\u2010333468"},{"key":"e_1_2_14_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16534"},{"key":"e_1_2_14_37_1","doi-asserted-by":"publisher","DOI":"10.1177\/13872877251331243"},{"key":"e_1_2_14_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70875"},{"key":"e_1_2_14_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100102"},{"key":"e_1_2_14_40_1","doi-asserted-by":"publisher","DOI":"10.3988\/jcn.2024.0550"},{"key":"e_1_2_14_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467\u2010026\u201071732\u20101"},{"key":"e_1_2_14_42_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2025.1232"},{"key":"e_1_2_14_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.71577"},{"key":"e_1_2_14_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474\u20104422(23)00274\u20100"},{"key":"e_1_2_14_45_1","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afac173"},{"key":"e_1_2_14_46_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195\u2010023\u201001272\u2010z"},{"key":"e_1_2_14_47_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.13855"},{"key":"e_1_2_14_48_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010024\u201002869\u2010z"},{"key":"e_1_2_14_49_1","unstructured":"Fujirebio \u201cFujirebio Announces CE Marking of the Fully Automated Lumipulse G pTau 217 Plasma Assay \u201d(2026) https:\/\/www.fujirebio.com\/en\/news\u2010events\/fujirebio\u2010announces\u2010ce\u2010marking\u2010of\u2010the\u2010fully\u2010automated\u2010lumipulser\u2010g\u2010ptau\u2010217\u2010plasma."},{"key":"e_1_2_14_50_1","unstructured":"Duodecim \u201cNeurodegenerative Disorders: Finnish Current Care Guidelines \u201d(2026) https:\/\/www.kaypahoito.fi\/hoi50044#s9."}],"container-title":["European Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ene.70786","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ene.70786","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ene.70786","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T07:41:17Z","timestamp":1792482077000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ene.70786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":49,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1111\/ene.70786"],"URL":"https:\/\/doi.org\/10.1111\/ene.70786","archive":["Portico"],"relation":{},"ISSN":["1351-5101","1468-1331"],"issn-type":[{"value":"1351-5101","type":"print"},{"value":"1468-1331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"2026-05-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70786"}}